ImmunityBio's Q1 Revenue Jumps 168% to Record $44M, Cash Nears $381M
IBRX has more than doubled off its 52-week low of $1.83.
Summary
ImmunityBio announced strong preliminary Q1 2026 results, reporting a record $44 million in net product revenue, representing a substantial 168% year-over-year increase. This performance continues the positive commercial trajectory for ANKTIVA, following the 700% revenue growth highlighted in the company's recent 2025 annual report. The company also reported a healthy cash and marketable securities balance of approximately $381 million at quarter-end. This significant revenue growth and solid cash position are highly material, indicating strong commercial execution and financial stability. Investors will monitor the upcoming full Q1 10-Q for detailed financials and further updates on ANKTIVA's market penetration and pipeline advancements, including the planned supplemental BLA submission.
At the time of this announcement, IBRX was trading at $6.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $1.83 to $12.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.